Back to the main directory
EarningsReview / Equity
- HUBS: Making a Bear Case Increasingly Difficult; Solid 3Q18; Reiterate Outperform by Raymond James
- TPIC: DOJ Isn't the Only One with Transitions... with Larger Blade Trend, 2019 Top Line Jumps 50% by Raymond James
- Persisting regulatory and operational uncertainties by BNP Paribas Exane
- Poor Q3, better outlook for Q4 by BNP Paribas Exane
- CEO hesitance to assume a quick end to WLTP distortion leaves optionality by BNP Paribas Exane
- SCM: Another Large Realized Gain, Strong 4Q Fee Income Expected; Reit. MO2 by Raymond James
- Oriflame (Buy, TP: SEK317.00) - Relief, and added confidence by DnB Markets
- Melia Hotels International: Q3 Results In-Line, but Q4 Outlook Mixed - Target Price Down to €12 by Raymond James
- AAOI: 3Q18 Report: Perhaps Its Own Worst Enemy, Trim Estimate, Maintain Outperform by Raymond James
- Delivering growth by BNP Paribas Exane
- Confident message on growth and profitability by BNP Paribas Exane
- Sampo Oyj (Hold, TP: EUR46.00) - Steady performance by DnB Markets
- AYX: Strong 3Q Beat and Raise, Continued Investment for Growth; Outperform by Raymond James
- Bioplastiques : un simple pansement sur la plaie de la pollution plastique by Oddo BHF
- CASA: 3Q18 Results: Beat With No Raise Leads To Puzzling 4Q18 by Raymond James
- Espresso | EDP Renovaveis | Buy | Low loads and adverse forex by Kepler Cheuvreux
- Better plan, more realistic targets, harsh reaction by BNP Paribas Exane
- FLSmidth (Buy, TP: DKK420.00) - Strong orders, weakening mix by DnB Markets
- HSKA: In a Dog-Eat-Dog Landscape, We Continue to Like Heska’s Positioning by Raymond James
- WK: Solid 3Q; Increasing Optimism for 2019; Risk/Reward Looks Balanced by Raymond James
- LBTY (Buy) - Q3 18: 4 year high for UK ARPU growth by New Street Research
- Q3 18 results: good figures on better margins by BNP Paribas Exane
- RGNX: 3Q18 Update: 4 Key Data Updates Expected in 2019 + Novartis Royalties by Raymond James
- Al Hokair – Opex efficiencies offset by higher other expenses by Tellimer
- CRSP: 3Q18 Update: First Beta-thalassmia Patient Enrolled by Raymond James